A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

Promrat, Kittichai, Lutchman, Glen, Uwaifo, Gabriel I., Freedman, Renee J., Soza, Alejandro, Heller, Theo, Doo, Edward, Ghany, Marc +6 more·2004·Hepatology
DOI 10.1002/hep.20012

Cited by (722)

Items 601–700 of 722

  1. Improvement of liver function tests by antidiabetic agents: The need for multidirectional analysis
    Bruno L Vergès, J.-M. Petit, Benjamin Bouillet · 2015 · Diabetes & Metabolism
  2. Tissue Distribution and Versatile Functions of PPARs
    Jihan Youssef, Mostafa Z. Badr · 2013 · Humana Press eBooks
  3. Transplantation for Nonalcoholic Steatohepatitis
    Ashwani Kumar Singal, Michael Charlton · 2015 · Elsevier eBooks
  4. Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
    Lucia Brodosi, Alessandra Musio, Francesca Alessandra Barbanti, Dorina Mita, Giulio Marchesini, Maria Letizia Petroni · 2020 · Hepatoma Research
  5. The Glycemic, Cardiovascular and Hepatic Outcomes of Pioglitazone Treatment: Evidence for Its Increased Use
    Mayer B. Davidson · 2020
  6. Carbohydrate, Fat, and Protein Metabolism in Obesity
    José Eduardo Galgani, Vı́ctor Cortés, Fernando Carrasco N · 2016 · Springer eBooks
  7. Liver Transplantation for Nonalcoholic Fatty Liver Disease
    Michael Charlton · 2008 · Humana Press eBooks
  8. Améliorer l’insulinorésistance : un progrès certain dans la prise en charge des malades atteints de stéato-hépatite non alcoolique… mais l’histoire continue
    Jean–François Cadranel, Vincent Jouannaud, Sylvie Loison · 2004 · Gastroentérologie Clinique et Biologique
  9. Resistencia a la insulina. Causa o consecuencia de la enfermedad hepática
    Vı́ctor Vargas · 2004 · Gastroenterología y Hepatología
  10. Pioglitazona. Revisión de sus efectos metabólicos y sistémicos
    Á. Rodríguez Bernardino, Sonia Cebrián Blanco, Santiago Durán García · 2005 · Revista Clínica Española
  11. Non-Alcoholic Fatty Liver Disease : A clinical and histopathological study
    Mattias Ekstedt · 2008 · DiVA (Linkoping University)
  12. SPECIAL REPORTS AND REVIEWS Nonalcoholic Fatty Liver Disease: Cytokine-Adipokine Interplay and Regulation of Insulin Resistance
    Herbert Tilg, Gökhan S. Hotamışlıgil · 2006
  13. Decades old glitazones still find niche in drug discoveries as PPAR-γ agonists: medicinal chemistry perspective, structure-activity relationships and therapeutic implications
    P. Archana, Thirumoorthy Durai Ananda Kumar, N. Vijaya Ganesh, Manal Mohammed, Harshal Pundalik Tavanoji, R Deepikarani, B. R. Prashantha Kumar · 2025 · Bioorganic & Medicinal Chemistry
  14. Non-Alcoholic Fatty Liver Disease (NAFLD), Adipocytokines and Diabetes Mellitus
    Dhastagir Sultan · 2011 · InTech eBooks
  15. Obesidad y enfermedad hepática
    María E. Miquilena-Colina, Carmelo García Monzón · 2010 · Gastroenterología y Hepatología
  16. Rosiglitazone: how should we be using this oral hypoglycaemic drug after studies indicating increased MI risk have resulted in changes in recommendations?
    Brian Karet · 2008 · Primary Care Cardiovascular Journal (PCCJ)
  17. Emerging drugs for complications of end-stage liver disease
    Joanna K. Dowman, Andrew P. Holt, Philip Noel Newsome, David Adams · 2008 · Expert Opinion on Emerging Drugs
  18. Pediatric Obesity and Non-alcoholic Fatty Liver Disease: Is It Real Problematic?
    Sang Gyune Kim · 2011 · Korean Journal of Gastroenterology
  19. Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes
    Phey Ming Yeap, Khalida Ann Lockman, Rob A. Elton, Margaret Boyd, Peter Clive Hayes, Alan J. Jaap · 2011 · The British Journal of Diabetes
  20. Non-Alcoholic Fatty Liver Disease
    Roula Hadyan Mohammed Alhadyan, Albader Abdulhameed Y. Khojah, Abdulaziz Ghareeb Abdullah Alanazi · 2018 · The Egyptian Journal of Hospital Medicine
  21. Long term effects of pioglitazone therapy with nonalcoholic steatohepatitis
    Haruo Nakayama, Shigetoshi Iwahasi, Toshiaki Ojima, Masao Kusano, Shigeyuki Asano, Yoshiki Sugai · 2009 · Kanzo
  22. Pioglitazone versus metformin in Egyptian non diabetic patients with Non Alcholic Fatty Liver Disease: A randomized controlled trial.
    Sahar K. Hgazy, Mamdouh Ahmed Gabr, Nahla E. El‐Ashmawy, Maha A. Younis · 2017 · IOSR Journal of Pharmacy (IOSRPHR)
  23. NASH
    Brent A. Neuschwander‐Tetri · 2006 · Elsevier eBooks
  24. Stellate Cells
    Fabio Marra, Sara Galastri, Sara Aleffi, Massimo Pinzani · 2009 · Springer eBooks
  25. Thiazolidinediones
    2015 · Elsevier eBooks
  26. Non-alcoholic Fatty Liver Disease - New Insight and Glance Into Disease Pathogenesis
    Seop Kang · 2022 · IntechOpen eBooks
  27. Novel Therapeutics in Nonalcoholic Fatty Liver Disease: A Focus on Adult Stem Cells
    Seshagiri Rao Nandula, Eric Nylén, Sabyasachi Sen · 2023 · Metabolic Syndrome and Related Disorders
  28. The Effect of Nanobubble Water Containing Cordyceps Extract and Withaferin A on Free Fatty Acid-Induced Lipid Accumulation in HepG2 Cells
    Hanlin Han, Yixin Sun, Weixu Zhang, Zhenya Zhang, Tian Yuan · 2023 · Nanomaterials
  29. Non alcoholic fatty liver disease (NAFLD): an overview
    NC McAvoy, Ann Lockman, P.C. Hayes · 2007 · The Journal of the Royal College of Physicians of Edinburgh
  30. Clinical Trial Report: Treatment of Nonalcoholic Steatohepatitis with Vitamin E
    Bruce R. Bacon · 2010 · Current Gastroenterology Reports
  31. The role of leptin and adiponectin in chronic liver diseases
    Emmanuel A. Tsochatzis, George Papatheodoridis · 2005 · UCL Discovery (University College London)
  32. Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis
    Ahmed Akhter, Abhishek Pulla, Adnan Said · 2016 · Clinical Liver Disease
  33. Diabetes and Non-alcoholic Fatty Liver Disease: Review
    Ayşen Akalın · 2016 · Turkiye Klinikleri Journal of Internal Medicine
  34. Fatty acid and glucose metabolism in upper body obesity : effects of diet and exercise compared to pioglitazone administration
    Samyah Shadid · 2007
  35. The Effect of Fenofibrate and Exercise on Metabolic Syndrome and Hepatic Steatosis in OLETF Rats
    Kyung-II Lee, Ji Min Kim, Ja Young Park, Ja Won Kim, Ji Young Mok, Mikyoung Park, Hye‐Jeong Lee, Sook Hee Hong, Wenjun Li, Duk Kyu Kim · 2007 · Journal of Korean Endocrine Society
  36. A case report of successful treatment with a cholesterol absorption inhibitor for decompensated burned-out NASH
    Kojiro Seki, Takanori Boku, Atsushi Umemura · 2009 · Kanzo
  37. Non‐alcoholic fatty liver disease: what is it, when does it occur, and why does it matter?
    David Preiss, Naveed A. Sattar · 2007 · Practical Diabetes
  38. Peut-on traiter la stéatohépatite métabolique ?
    Vlad Ratziu, Maria Vispo, Mohamed Tahiri, Luminita Bonyhay, Mercedes de Torres, Carole Bernhardt, Thierry Poynard, Pascal Lebray · 2007 · Gastroentérologie Clinique et Biologique
  39. Stéatopathies hépatiques non alcooliques
    Pierre Lahmek, Stéphane Nahon · 2005 · EMC - Hépato-Gastroenterologie
  40. Thiazolidinediones in NASH An Odd Couple Meant To Be?
    Kenneth J. Cusi · 2009 · Journal of Clinical Gastroenterology
  41. Pathogenesis and Management of Non-alcoholic Steatohepatitis
    Sang Hoon Park, Choong Kee Park · 2005 · Journal of the Korean Medical Association
  42. Therapeutic strategies in nonalcoholic fatty liver disorders
    Fred F Poordad · 2005 · Expert Opinion on Emerging Drugs
  43. Rosiglitazone Activates AMPK and Improves Non-Alcoholic Fatty Liver Disease in OLETF Rats
    Eun-Hee Cho, Ki‐Up Lee · 2008 · Korean Diabetes Journal
  44. [Therapeuric aspects of NAFLD. A literature review].
    Norberto Carlos Chávez Tapia, Félix Ignacio Téllez-Ávila, Jorge García-Leiva, Martha Helena Ramos, J.F. Sánchez-Ávila, Misael Uribe · 2006 · PubMed
  45. Nonalcoholic Fatty Liver Disease
    Poonam Mishra, Nila Rafiq, Zobair M. Younossi · 2008 · Cambridge University Press eBooks
  46. Metabolic Diseases
    David A. Tendler · 2006
  47. Neue Therapiemöglichkeiten bei nichtalkoholischer Fettleber
    Thomas Pusl, Burkhard Göke · 2007 · Der Diabetologe
  48. Efeito anti-fibrogênico do doador de óxido nítrico S-nitroso-N-acetilcisteína (SNAC) na esteato-hepatite não alcóolica experimental
    Daniel Ferraz de Campos Mazo · 2012 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  49. NASH - Diagnostik und Therapie: eine Übersicht
    Christian Zauner, Alois Zauner, Reem Abou Assi, Patrick Manfred Brunner, E Grafl, Eduardo Alexandre Hofstätter, Michael Kleinberger, Buko Lindner, C Putz, N Roszuzcky et al. · 2007 · Journal für Kardiologie (Krause & Pachernegg GmbH)
  50. Uso de la técnica de perifusión de células hepáticas de rata en la investigación de las acciones metabólicas y mitocondriales directas de dos tiazolindionas, pioglitazona y rosiglitazona
    Maria de las Nieves Sanz García · 2010
  51. Interventions thérapeutiques prometteuses dans un modèle in vivo de stéatohépatite non alcoolique
    Yara K. Haddad · 2008
  52. Drug Therapy for NASH: Insulin‐Sensitizing Agents (Metformin and Thiazolidinediones)
    Mohammad Shadab Siddiqui, Arun Jayant Sanyal · 2013 · Wiley eBooks
  53. Classifications, Scoring Systems and Morphometry in Liver Pathology
    Pierre Bédossa, Valérie Paradis · 2007
  54. Liver Biopsy in Transplantation: Nonalcoholic Fatty Liver Disease and the Eosinophils
    Yasuhiko Sugawara, Norihiro Kokudo, Yoji Kishi · 2011 · InTech eBooks
  55. Association Between Fatty Liver and Cardiovascular Disease: Mechanism and Clinical Implications
    William Nseir, Nimer Assy · 2011 · InTech eBooks
  56. Leitfaden für die Praxis - Unklar erhöhte Transaminasen und die klinische Bedeutung der nichtalkoholischen Fettleber
    Max Karner, Wolfgang Stremmel · 2004 · Der Klinikarzt
  57. Pentoxifylline: not just for alcoholic hepatitis anymore?
    Roman E. Perri, Vijay H. Shah · 2008 · Hepatology International
  58. Type 2 Diabetes in Children and Adolescents: Treatment
    Philip Scott Zeitler · 2007 · Obesity Management
  59. Nonalcoholic Fatty Liver Disease in Pediatric Patients
    Shikha S. Sundaram, Kristen J. Nadeau · 2009 · Obesity Management
  60. What's new in … Liver disorders
    Rebecca Saich, Roger William Chapman · 2002 · Medicine
  61. Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis
    Janet C. King, Kris V. Kowdley · 2007 · Hepatology
  62. Pediatricians’ IQ on RDS, NAFLD, and Syndrome X
    I. David Schwartz · 2006 · The Journal of Pediatrics
  63. PPAR-δ Agonist Rescue of Brain Insulin/IGF Signaling Impairments Following Developmental Exposure to Alcohol
    Alexandra Ewenczyk, Ashley Conoway, Jason L. Ziplow · 2013 · Journal of Drug and Alcohol Research
  64. Vers un traitement médical de la stéatohépatite non alcoolique ?
    Alexandre Louvet, Philippe Mathurin · 2005 · Gastroentérologie Clinique et Biologique
  65. Компьютерные Науки : Учеб. Пособие. В 4 Частях. Часть 4. Системы Искусственного Интеллекта
    Evgeny Cherkashi · 2014 · INFM-OAR (INFN Catania)
  66. Nutritional regulation of central fat mass and obesity-associated (FTO) expression, and its association with the central melanocortin signaling in the regulation of energy homeostasis
    Nicole J. Poritsanos · 2010 · Mspace (University of Manitoba)
  67. Normal alanin aminotransferaz düzeyli nonalkolik yağlı karaciğer hastalığında insülin direnci ve metabolik sendrom
    Ebru Gök Oğuz, Enver Uçbılek, Orhan Sezgın · 2015 · Akademik Gastroenteroloji Dergisi
  68. "Alterações hepáticas em grandes obesos: avaliações clínico-laboratoriais e histopatológicas antes do tratamento cirúrgico da obesidade"
    Cacilda Pedrosa de Oliveira · 2006
  69. Stéatohépatite non alcoolique
    H. Castel, Philippe Mathurin · 2011 · EMC - Endocrinologie - Nutrition
  70. Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
    Samer Gawrieh, Naga Chalasani · 2015 · Springer eBooks
  71. Editorial NASH and thiazolidinediones: Not to be taken lightly q
    Jean-François Dufour · 2007
  72. The Relationship between Liver Fat Content and Unenhanced Computed Tomography
    Karen Shoebotham · 2009 · Europe PMC (PubMed Central)
  73. 生活習慣と肝臓病：診断と治療の進歩 ＩＶ．非アルコール性脂肪肝炎（ＮＡＳＨ）６．ＮＡＳＨの治療
    河田 純男 · 2006 · Nihon Naika Gakkai Zasshi
  74. A Review of Pharmacological Treatments of NASH
    Érika Rabelo Forte de Siqueira · 2015 · Gastroenterology & Hepatology Open Access
  75. Childhood obesity, nutrition and metabolic health
    Michael I. Goran, Martha Liliana Cruz, Gabriel Q. Shaibi, Marc J. Weigensberg, Donna Spruijt‐Metz, Cara B. Ebbeling, David S. Ludwig · 2005 · Elsevier eBooks
  76. Should physicians be prescribing or patients self‐medicating with orlistat, vitamin E, vitamin D, insulin sensitizers, pentoxifylline, or coffee?
    Haripriya Maddur, Brent A. Neuschwander‐Tetri · 2016
  77. Diagnóstico e Tratamento da Esteato ratamento da Esteato ratamento da Esteato ratamento da Esteato ratamento da Esteato-Hepatite Não Alcóolica -Hepatite Não Alcóolica -Hepatite Não Alcóolica -Hepatite Não Alcóolica -Hepatite Não Alcóolica Diagnosis and Treatment of Nonalcoholic Steatohepatitis
    Helena Cortez‐Pinto · 2006
  78. Nutritional Status of Patients with End Stage Liver Disease: An Outpatient Assessment
    Anna Cumming-Browne Hefner · 2013
  79. Revisión de los tratamientos farmacológicos actuales y futuros de la esteatohepatitis no alcohólica
    Ahmed Akhter, Abhishek Pulla, Adnan Said · 2016 · Clinical Liver Disease
  80. Targets for Therapy and Current Status of Treatment for NAFLD
    Keith D. Lindor, Leon Anton Adams · 2005 · UWA Profiles and Research Repository (University of Western Australia)
  81. An Update of Liver Transplantation for Nonalcoholic Steatohepatitis
    I. Raymond Thomason, Michael Charlton · 2015 · Current Hepatology Reports
  82. TWO CASES OF NON ALCOHOLIC FATTY LIVER DISEASE WHERE LAPAROSCOPY AND LIVER BIOPSY WERE USEFUL FOR DISTINGUISHING AUTOIMMUNE HEPATITIS
    Kazuhisa Nakamura, Yoshihisa Sato, Noriyuki Asaba · 2006 · Acta gastro-enterologica belgica
  83. ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials
    Rohit Seth Loomba, ROBERT A. WESLEY, Frank Pucino, Tiebing Liang, David Erwin Kleiner, Joel E. Lavine · 2008
  84. New pharmacological approaches in type 2 diabetes mellitus
    Kenneth J. Cusi · 2009 · Dialnet (Universidad de la Rioja)
  85. Recent Advances
    Richard Kirsch, Pauline de la Μ. Hall, Jacob George, Arthur J. McCullough, Geoffrey C. Farrell · 2004
  86. Effects of Vitamin E in non alcoholic fatty liver disease
    R Divakar · 2018
  87. Examination of the scientific evidences for off-label use of medications in non-alcoholic fatty liver disease
    Gabriela Correia Matos de Oliveira, Gustavo Magno Baptista, Elizabel Izidorio Lima, Alcina Maria Vinhaes Bittencourt, Luís Jesuino De Oliveira Andrade · 2019 · Revista de Ciências Médicas e Biológicas
  88. Non alcoholic fatty liver disease: pathogenesis, role of (TNF-α, IL-6) in hepatic inflammation and future potential nutraceutical treatment
    Safaa A. Faheem, Noha M. Saeed, Reem N. El‐Naga, Samar S. Azab · 2019 · Archives of Pharmaceutical Sciences Ain Shams University
  89. Pediatric Diabetes: Review Article
    B. Bavishna, R. Uma Devi, S. Gopala Krishnan · 2019 · Indian Journal of Public Health Research & Development
  90. Recurrent Primary Disease After Liver Transplantation
    Varun Saxena, Norah A. Terrault · 2018 · Elsevier eBooks
  91. TXN, a Xanthohumol Derivative, Attenuates High-Fat Diet Induced Hepatic Steatosis by Antagonizing PPARγ
    Yang Zhang, Gerd Bobe, Cristobal L. Miranda et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  92. CLINICAL PROFILE OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS
    Sayed Mohammed Meraj Hussaini · 2015
  93. Gyrate Atrophy, High myopia, Night blindness, Ornithine Aminotransferase, Posterior sub capsular cataract.
    G Satyavathi, Y Srinivas, Malleswari · 2015
  94. Diabetes and Liver Disease
    Robert P. Hirten, Henry Charles Bodenheimer, David Bernstein · 2017 · Springer eBooks
  95. Diabetes and Liver Disease
    Robert P. Hirten, Henry Charles Bodenheimer, Douglas Meyer, David Bernstein · 2017 · Springer eBooks
  96. Diabetes and Liver Disease
    Robert P. Hirten, Henry Charles Bodenheimer, David Bernstein · 2015 · Springer eBooks
  97. Consequences of the Metabolic Syndrome
    2007 · Springer eBooks
  98. Childhood obesity, nutrition and metabolic health
    Michael I. Goran, M. Cruz, Gabriel Q. Shaibi, Marc J. Weigensberg, Donna Spruijt‐Metz, C.A. Ebbeling, David S. Ludwig · 2010 · Woodhead Publishing Limited eBooks
  99. INSULINS AND OTHER HYPOGLYCEMIC DRUGS
    2009 · Elsevier eBooks
  100. Selected Organ System Abnormalities
    2007 · Elsevier eBooks